Navigation Links
Development and clinical approval of biodegradeble magnesium alloy
Date:11/12/2013

This biodegradable and bioabsorbable metal decomposes from 6 months to 2 years after being transplanted into human body and hence, medical devices made with these materials are expected to reshape the landscape in the field of fracture treatment, as it reminders second operation to take out the device after patient recovery obsolete. KIST Consortium Consortium participated by U & I (Co.), ASAN Medical Center and Seoul National University (led by Dr. Seok, Hyun-kwang of KIST Biomedical Research Institute) succeeded in developing high strength/low biodegradable metal made from basic elements and minerals essential to human body. The Consortium also developed biodegradable and bioabsorbable medical devices for use in orthopedics & plastic surgery while earning approval to clinically test the device. The clinical trial is currently in progress conducted by Ajou University Medical Center. The heart of the research is matching potentials between the matrix structure of metal and the secondary agents on the matrix structure to overcome the fundamental limitation of metal materials, which is speedy degradation. Using this application, new innovative materials can be developed such as metal alloy with the 2nd and 3rd additional elements while still maintaining the electrochemical nature of pure metal. The remarkable achievement was made possible thanks to the Computational Materials Science Laboratory at Kookmin University (led by Professor Cha Phil-ryung), which helped to create the effects of synergy between computer simulation and technology. With extensive support of the Seoul Strategic Industry Initiative, the key support program of the Seoul City government for Smaller enterprises' R&D, KIST Consortium has succeeded in developing new degradable metal materials inside human body after transplant, and also received approval to clinically test these metals from the Korea Ministry of Food and Drug Safety as a bioabsorbable fixation device to be used in orthopedics and plastic surgery. KIST was selected as a beneficiary for the Seoul Strategic Industry Support Initiative in 2010 and has been working on the project for 3 years. Further, these findings were published in the 2013 August edition of Scientific Report, a sister magazine of the world-renowned scientific journal, Nature.


'/>"/>

Contact: Dr. Hyunkwang Seok
drstone@kist.re.kr
82-106-310-6738
Korea Institute of Science and Technology
Source:Eurekalert  

Related biology news :

1. Regenerative Sustainable Development of Universities and Cities
2. Fast-mutating DNA sequences shape early development; guided evolution of uniquely human traits
3. Exercise during pregnancy gives newborn brain development a head start
4. Allen Institute for Brain Science partners with imec for development of next-generation tools
5. Brain may play key role in blood sugar metabolism and development of diabetes
6. As world sets new development goals, Malaysia calls for poverty relief within green agenda
7. NIH funds development of novel robots to assist people with disabilities, aid doctors
8. EUREKA grant to fund development of new optogenetic technique for mapping neural networks at UMMS
9. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
10. Frontiers launches a new open-access journal in Cell and Developmental Biology
11. Oncogenic signatures mapped in TCGA a guide for the development of personalized therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Development and clinical approval of biodegradeble magnesium alloy
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: